Clinical trials: HIV Infected Individuals
HIV-1 Infection
High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART
This study was done with people who were infected with HIV and needed to start treatment for their HIV disease. The purpose of this study is to see if taking vitamin D and calcium will help prevent the bone loss that sometimes…
- Trial name
- NCT01403051
- Testing
- EFV/FTC/TDF, Calcium Carbonate, Vitamin D3
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 167 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infections
Antiretroviral Therapy Intensification With Raltegravir or Addition of Hyper-immune Bovine Colostrum in HIV-1 Infected Patients With Suboptimal CD4+ T Cell Response
A research study to measure the effect on CD4 counts of adding to current anti-retroviral regimen raltegravir with or without hyper-immune bovine colostrum.
- Trial name
- CORAL (NCT00772590)
- Testing
- Raltegravir, Hyper-immune Bovine Colostrum, raltegravir and hyper-immune bovine colostrum
- Volunteers
- 75 people
- Sponsor
- Kirby Institute
HIV Infections
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
The purpose of this study was to compare the efficacy, safety, and durability of two different strategies to treat participants with a history of sub-optimal adherence and control of their HIV infection: long-acting (LA)…
- Trial name
- NCT03635788
- Testing
- Standard of Care (SOC) Oral ART, Oral RPV, Oral CAB
- Where
- 33 sites in United States, Puerto Rico
- Volunteers
- 456 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection
Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on Antiretroviral Therapy (ART)
This is a phase I, single-site, study to evaluate the effects of VOR and HIV-1 Antigen Expanded Specific T Cell Therapy (HXTC) on persistent HIV-1 Infection in HIV-infected individuals suppressed on ART.
- Trial name
- XTRA (NCT03212989)
- Testing
- Vorinostat, HXTC
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV-1-infection
ART First-line Treatment Durability in Russia
This study is a non-interventional retrospective study. Data from patients who signed informed consent form will be collected through retrospective chart or medical records review.
- Trial name
- NCT04253119
- Testing
- Antiretroviral/Anti HIV
- Where
- 4 sites in Russia
- Volunteers
- 536 people
- Sponsor
- MSD Pharmaceuticals LLC
HIV/AIDS
Impact of Metformin on Immuno-virologic Parameters in HIV
Non-diabetic, aviremic HIV-infected individuals on antiretroviral therapy (ART) will be randomized to metformin therapy or to observation for 72 weeks.
- Trial name
- NCT04500678
- Testing
- Metformin
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Hawaii
HIV
Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals
The project will have two tracks, one for participants who are currently taking elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate or E/C/F/tenofovir alafenamide (E/C/F/TDF or E/C/F/TAF) single-tablet regimen*…
- Trial name
- NCT02251236
- Testing
- Stribild, Genvoya
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of California, San Diego
Human Immunodeficiency Virus
3BNC117-LS First-in-Human Phase 1 Study
The proposed study is a phase 1 study of the mAb 3BNC117-LS administered intravenously in HIV uninfected individuals and HIV-infected individuals, and subcutaneously in HIV-uninfected individuals.The objectives of the study are…
- Trial name
- NCT03254277
- Testing
- 3BNC117-LS
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
HIV Infection
Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals
The purpose of this study is to determine the safety, toxicity, dosing, and antiviral effects of epigallocatechin gallate (EGCG) in capsule form (Polyphenon® E), administered orally twice daily at three different doses in…
- Trial name
- NCT01433289
- Testing
- Polyphenon E
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Baylor College of Medicine
HIV
Combination Therapy With VRC01 and 10-1074 in HIV-Infected Individuals Undergoing Sequential Treatment Interruptions
Background: A daily drug combination can keep human immunodeficiency virus (HIV) levels low for a long time. But if this combination antiretroviral therapy (ART) stops, HIV levels go back up.
- Trial name
- NCT03831945
- Testing
- VRC-HIVMAB060-00-AB (VRC01), 10-1074
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, Human Immunodeficiency Virus
Immunologic Response to Kansui in Treated HIV+ Individuals: a Dose Escalation Study
The purpose of this study is to determine the safety and bioactivity of an herbal supplement called "kansui," which contains several active ingredients such as ingenols that may have a role in helping clear HIV from the body.
- Trial name
- NCT02531295
- Testing
- Euphorbia kansui extract powder prepared as tea
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of California, San Francisco
HIV-1 Infection
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
This study is being done to see whether rifaximin, an antibiotic that works in the intestines, can lower the amount of germs in the intestines of HIV infected persons.
- Trial name
- NCT01466595
- Testing
- Rifaximin
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 73 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Staphylococcus Aureus, HIV Infections
Rifabutin Based Therapy for the Eradication of Staphylococcus Aureus Colonization in HIV Infected Adults
DESIGN: This single center, double-blinded, randomized phase II study is being conducted to assess the efficacy of a rifabutin based regimen to eliminate S. aureus colonization in HIV infected individuals.
- Trial name
- NCT00869518
- Testing
- rifabutin plus trimethoprim sulfamethoxazole
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, San Francisco
HIV Infections, Cardiovascular Disease
Effect of Rosuvastatin on Endothelial Function
Rosuvastatin belongs to a class of medications commonly called "statins" which are medications given for high low density lipoprotein (LDL) 'bad' cholesterol to prevent atherosclerosis (hardening of blood vessels) and lower risk…
- Trial name
- NCT00986999
- Testing
- rosuvastatin
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- University of Hawaii
Tuberculosis, HIV Infections
Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)
HIV-infected people have an increased risk of developing active tuberculosis (TB). At the time the study was designed, the standard course of treatment for TB was 6 to 9 months of isoniazid (INH).This study compared the safety…
- Trial name
- NCT01404312
- Testing
- Rifapentine (RPT), Isoniazid (INH), Pyridoxine (Vitamin B6)
- Where
- 45 sites in United States, Botswana and 8 more
- Volunteers
- 3,000 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
H1N1 Influenza Vaccine Immunogenicity in HIV-1 Infected Patients
The overall goal of this study is to study influenza vaccine responses in HIV infected individuals. Immunocompromised individuals require special protection from influenza, but may not respond appropriately to the standard killed…
- Trial name
- NCT01111162
- Testing
- H1N1 vaccination
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Pennsylvania
HIV
BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.
The purpose of this Phase IV pilot study is to evaluate the safety, tolerability, and satisfaction of a nucleoside analog reverse-transcriptase inhibitors (NRTI)sparing regimen for participants fully suppressed on an…
- Trial name
- BATAR (NCT00931801)
- Testing
- atazanavir/raltegravir, atazanavir/tenofovir/emtricitabine
- Where
- 9 sites in United States
- Volunteers
- 43 people
- Sponsor
- Community Research Initiative of New England
Acute HIV Infection
Effects of Intensive cART During Acute/Early HIV Infection
This trial will investigate the efficacy and safety of intensified antiretroviral treatment that includes raltegravir and maraviroc during the early stages of HIV infection.
- Trial name
- NCT01154673
- Testing
- raltegravir, maraviroc, emtricitabine 200mg /tenofovir 300mg
- Where
- 2 sites in Canada
- Volunteers
- 32 people
- Sponsor
- University of Toronto
HIV-1-infection
MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy
This is a Phase 1, open-label single-center study to determine the safety of MGD014 in participants with human immunodeficiency virus (HIV) infection on stable suppressive antiretroviral therapy (ART).
- Trial name
- NCT03570918
- Testing
- MGD014
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- MacroGenics
HIV
Improving Memory Performance by Applying Cognitive Training
The proposed study will test the efficacy of a cognitive training program to improve working memory in a sample of HIV-infected persons.
- Trial name
- IMPACT (NCT02216591)
- Testing
- Active Cognitive Training (ACT), Control (CON)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Duke University